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Abstract 
  
Adenosine triphosphate (ATP) is co-released together with acetylcholine (ACh) 
upon electrical stimulation of motor nerve terminals (Magalhães-Cardoso et al., 2003). 
Released ATP modulates neuromuscular transmission either by directly activating P2 
purinoceptors (P2R) (Salgado et al., 2000) or indirectly through the activation of P1 
receptors after being metabolized into adenosine (ADO), via ecto-nucleotidases 
(Correia-de-Sá et al., 1996). Adenosine derived from the extracellular catabolism of 
ATP activates preferentially excitatory A2A receptors at stimulated motor nerve 
terminals (Correia-de-Sá et al., 1996; Cunha et al., 1996a). We have recently 
demonstrated that tonic activity of A2AR is impaired in Myasthenia gravis probably due 
to low levels of endogenous ADO accumulation (Oliveira et al., 2015a) indicating that 
neuromuscular transmission failure is associated to deficits in the ADO pathway. 
Considering the crucial role of ATP on neuromuscular transmission mediated by P1 
and P2 receptores we decided to evaluate the amounts of endogenous ATP release as 
well as extracellular catabolism of ATP at the rat neuromuscular junction from an 
experimental autoimmune Myasthenia gravis (EAMG) animal model. Moreover, ATP 
modulation of neurotransmitter release was also evaluated in health and EAMG model. 
EAMG was induced in Wistar rats through immunization with R97-116 peptide, an 
immunogenic sequence of the α subunit of the rat nicotinic AChR (Oliveira et al., 
2015a). Control animals received the CFA emulsion without the peptide. Animals from 
the Naïve group were not submitted to treatment. Phrenic nerve hemidiaphragm 
preparations were isolated and the release of [3H]ACh and ATP was evoked by phrenic 
nerve stimulation with 5 Hz-trains (750 pulses of 0.04 ms duration). ATP and [3H]ACh 
content was measured by the luciferin-luciferase bioluminescence assay and by liquid 
scintillation spectrometry, respectively, and kinetics of the extracellular ATP catabolism 
by HPLC (UV Detetion). 
EAMG animals exhibited an increased levels of electrically induced ATP release 
(0,139±0,039 pmol/mg, n=4) comparatively to CFA (0,051±0,006 pmol/mg, n=6) 
animals. The increased accumulation in the bath effluent of ATP is not related to a 
decrease in ATP catabolism at rat motor nerve terminals from EAMG rats. In fact, ATP 
(30 µM) catabolism was increased since the half-degradation time of ATP was 
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decreased in EAMG (5±1 min, n=4) animals comparatively to Naïve (8±2 min, n=8) 
rats.  In parallel, an increased accumulation for the metabolite ADP, during the firsts 15 
minutes of ATP metabolism, was quite evident in EAMG animals. The rat motor nerve 
terminals seems to be equipped with inhibitory P2R, since the slowly hydrolysable 
analogue of ATP, βImidoATP (100 µM) inhibited (21±11%, n=3) neurotransmitter 
release. However, the presynaptic inhibitory P2 receptores are only operative in the 
absence of ADO since ATP (1 µM) only presented an inhibitory effect (1) in the 
presence of adenosine deaminase (ADA 0,5 U/mL), the enzyme that inactivates ADO 
into INO (32±18%, n=4), and when incubated for shorter periods (3 min) which impairs 
ADO accumulation from ATP catabolism. Interestingly, this results points to a possible 
crosstalk between presynaptic inhibitory P2R and facilitatory A2AR. However, this 
hyphotesis needs to be clarified in our experimental conditions. Nevertheless it has 
been recently documented a similar interaction in other systems, like the bladder (Yu et 
al., 2014). In the same way, the inhibitory effect of P2R was only observed at the rat 
motor nerve terminals from EAMG animals when ATP (1 µM) was applied with 3 
minutes incubation (41±3%, n=2). Despite the fact we have not collected direct 
evidences for an higher susceptibility of presynaptic inhibitory P2R to desensitization in 
EAMG animals, we may speculate that this fenomema is operating in EAMG animals 
since (1) they exhibited higher amounts of evoked release ATP (2) the ATP metabolite 
ADP, a ligand for inhibitory P2R like P2Y12 and P2Y13 receptors, accumulates in higher 
concentrations at the synaptic cleft comparatively to naïve animals and (3) P2Y12R 
have been reported to be desensite in other systems, like bladder and plaquets. In 
addition, application of ATP (1 µM) 15 min prior stimulus recovered A2AR activity in 
EAMG animals since ATP (1 µM) facilitated [3H]ACh release by (43±12%, n=5) and in 
the presence of ADA (0,5 U/mL), failed to affect transmitter (5±17%, n=4) 
In conclusion, ATP modulates neurotransmitter release at rat motor nerve terminals 
from both healthy and EAMG animals by activating P2R and A2AR. In spite of that, 
activation of presynaptic facilitatory A2AR activation prevails over inhibitory P2YR which 
may resuly from higher susceptibility to desensitization of P2YR probably due to a 
crosstalk with A2AR. 
 
Keywords: ATP, Neuromuscular transmission, Myasthenia Gravis, nAChR, 
experimental autoimmune Myasthenia gravis (EAMG). 
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O ATP (adenosina trifostato) é libertado juntamente com a acetilcolina (ACh) 
mediante estimulação elétrica dos terminais nervosos motores (Magalhães-Cardoso et 
al., 2003). Uma vez libertado, o ATP pode modular diretamente a transmissão 
neuromuscular, através da ativaçao de purinorecetores P2 (P2R) (Salgado et al., 
2000) ou indiretamente através da ativação de recetores P1 após ter sido 
metabolizado em adenosina (ADO) pela via das ecto-nucleotidases (Correia-de-Sá et 
al., 1996). A adenosina resultante do catabolismo extracelular do ATP ativa 
preferencialmente os recetores excitatórios A2A nos terminais nervosos motores 
(Correia-de-Sá et al., 1996, Cunha et al., 1996a). O nosso grupo demonstrou 
recentemente que a atividade tónica dos A2AR encontra-se comprometida na 
Myasthenia gravis.  Esta alteração está associada à diminuição nos níveis endógenos 
de ADO (Oliveira et al., 2015a), sugerindo que o comprometimento da transmissão 
neuromuscular em EAMG poderá envolver alterações funcionais na via de conversão 
do ATP em ADO.  
Considerando o papel crucial do ATP na transmissão neuromuscular mediado por 
recetores P1 e P2 decidimos avaliar os níveis endógenos de ATP, bem como o 
catabolismo extracelular do ATP na junção neuromuscular no modelo experimental 
auto-imune de Miastenia gravis (EAMG). Além disso, a modulação da libertação do 
ATP também foi avaliada em animais saudáveis e modelos EAMG.  
O modelo animal EAMG foi induzido em ratazanas Wistar por meio de imunização 
com o péptido R97-116, uma sequência imunogénica da subunidade α do recetor 
nicotínico da acetilcolina (Oliveira et al., 2015a). Os animais do grupo controlo 
receberam a emulsão de CFA sem o péptido. Os animais do grupo Naïve não foram 
submetidos ao tratamento. As preparações dos hemidiagramas dos nervos frénicos 
foram isoladas e a libertação de ACh e ATP foi induzida pela estimulação do nervo 
frénico com 750 pulsos (duração de 0,04 ms) aplicados com uma frequência de 5 Hz. 
A avaliação dos níveis endógenos de ATP e a libertação de [3H]acetilcolina foram 
avaliadas pelo ensaio de bioluminescência luciferina-luciferase e por espectrometria 
de cintilação líquida, respectivamente. O catabolismo do ATP extracelular foi avaliado 
por HPLC (UV Detetion).  
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Nos animais EAMG observou-se um aumento nos níveis de libertação de ATP 
induzido por estimulação elétrica (0,139±0,039 pmol/mg, n=4) comparativamente com 
os animais CFA (0,051±0,006 pmol/mg, n=6 animais). O aumento dos níveis 
endógenos de  ATP não está relacionado com uma diminuição do seu catabolismo nos 
terminais nervosos motores de ratazana EAMG, uma vez que o tempo de semi-vida do 
ATP foi menor no modelo EAMG (5±1 minutos, n=4), comparativamente com os 
animais Naïve (8±2 min, n=8). Em paralelo, observou-se um aumento da acumulação 
de ADP, durante os primeiros 15 minutos de metabolismo do ATP, nos  animais 
EAMG. O análogo estável, βImidoATP (100µM), inibiu (21±11%, n=3) a libertação do 
neurotransmissor, sugerindo que os terminais nervosos motores de ratazana possuem 
recetores P2 inibitórios. Estes recetores P2 inibitórios pré-sináticos exercem o seu 
efeito modulador apenas  na ausência de ADO e consequente atividade dos  A2AR 
dado  que o ATP (1µM) apenas exibiu um efeito inibitório (1)  na presença da 
desaminase da adenosine (ADA 0,5 U/mL), a enzima que inativa a ADO em INO 
(32±18%, n=4), e (2) quando incubado durante períodos mais curtos (3min) que 
envolvem a perda de acumulação de ADO a partir do catabolismo de ATP. 
Curiosamente, estes resultados apontam para uma possível interação entre os 
recetores pré-sináticos inibitórios P2R e A2AR facilitatórios. No entanto é necessário 
esclarecer esta hipótese nas nossas condições experimentais, até porque foi 
recentemente documentada uma interação semelhante em outros sistemas, como a 
bexiga (Yu et al., 2014).  Da mesma forma, o efeito inibitório de P2R na modulação da 
transmissão neuromuscular dos animais EAMG foi apenas observado quando o ATP 
(1µM) foi aplicado com 3 minutos de incubação (41±3%, n=2). Apesar de não se ter 
recolhido evidências diretas para uma maior susceptibilidade do P2R pré-sinático 
inibitório para o fenómeno de dessensibilização nos animais EAMG, podemos 
especular que este mecanismo está a ocorrer em condições de miastenia  uma vez 
que o modelo EAMG (1) que exibiu um aumento dos níveis endógenos ATP,  (2) o 
metabolito do ATP, ADP, um ligando para os P2R como P2Y12 e P2Y13, acumula-se 
em concentrações mais elevadas na fenda sinática e (3) os P2Y12R apresentam 
elevada susceptibilidade para a dessensibilização em outros sistemas, como tem sido 
referido em bexiga e plaquetas. Adicionalmente, a aplicação do ATP (1µM) 15 minutos 
antes do estímulo recupera a atividade dos A2AR em animais EAMG, uma vez que o 
ATP (1µM) facilitou a libertação de [3H] ACh (43±12%, n=5) e na presença de ADA 
(0,5 U/ml), não conseguiu modificar a libertação do neurotransmissor (5±17%, n=4).  
Em conclusão, ATP modula a libertação de neurotransmissores nos terminais 
nervosos motores de ambos os animais, saudáveis e EAMG, ativando P2R e 
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A2AR. Apesar disso, a ativação pré-sináptica dos A2AR facilitatórios prevalece sobre a 
ativação P2YR inibitórios o que poderá ser devido a uma maior susceptibilidade para a 
dessensibilização dos P2YR provavelmente devido a uma interação com A2AR. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Palavras-chave: ATP, Transmissão neuromuscular, Miastenia gravis, nAChR, modelo 
experimental auto-imune de Miastenia gravis (EAMG). 
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1. Introduction 
1.1. Myasthenia Gravis - Pathophysiology 
Myasthenia gravis (MG) is a B-cell-mediated, T-cell-dependent autoimmune 
disease characterized by excessive muscle weakness and fatigue (Zuckerman et al., 
2010). The target of the autoimmune attack in most cases is the skeletal muscle 
acetylcholine receptor (AChR), but in others non-AChR components of the 
neuromuscular junction, such as the muscle-specific receptor tyrosine kinase may also 
be targeted (reviewed by Juel and Massey, 2007). These antibodies reduce the 
number of effective receptors to nearly one-third of the normal (Lindstrom, 2000) 
leading to a decrease in the safety margin of the neuromuscular transmission, which is 
particularly relevant during high-frequency nerve activity. Furthermore, the typical deep 
junctional folds are replaced by a relatively flat surface. The breakdown of self-
tolerance in the thymus apparently leads to the development of anti-AChR 
autoantibodies (Baggi et al., 2012; Melms et al., 2006; Newsom-Davis et al., 1981) with 
induction or activation of AChR-specific CD4+ T helper cells and production of pro-
inflammatory cytokines, consequently leading to the synthesis of high-affinity 
antibodies (Hoedemaekers et al., 1997; Vincent et al., 2003). Therefore, T cells play a 
pivotal role in MG since they lead the attack to the endplates by recognition of the 
antigen coupled to the major histocompatibility complex (MHC) class II molecules, 
promoting B cell production of anti-AChR antibodies by plasmocytes (Aricha et al., 
2006; reviewed by Juel and Massey, 2007; Vincent et al., 2003). 
 
1.1.2. Diagnostic 
MG remains one of the most challenging medical diagnoses due to its fluctuating 
character and to the similarity of its symptoms to those of other disorders (reviewed by 
Juel and Massey, 2007). Although a formal clinical classification system and research 
standards have been established for MG, there are no generally accepted formal 
diagnostic criteria. The most essential elements of diagnosis are clinical history and 
examination findings of fluctuating and fatigable weakness, mostly involving extraocular 
and bulbar muscles. A clinical diagnosis may be confirmed by laboratory testing 
including a pharmacologic testing with edrophonium chloride (Tensilon test), an 
acetylcholinesterase inhibitor, that elicits unequivocal improvement in strength; an 
electrophysiologic testing, with repetitive nerve stimulation (RNS) studies and/or single-
fiber electromyography (SFEMG) that demonstrates a primary postsynaptic 
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neuromuscular junctional disorder; or by serological demonstration of AChR or MuSK 
antibodies (reviewed by Juel and Massey, 2007). 
 
1.1.3. Symptoms 
MG is characterized by varying degrees of weakness to the muscles of the body, 
and most commonly affects the muscles that control the eyes, facial expressions, 
chewing, talking and swallowing. The disease can also affect muscles associated with 
breathing, neck and limb movement (Téllez-Zenten et al., 2004). Approximately 50 
percent of people with MG present with ocular symptoms of ptosis and/or diplopia. 
About 15 percent present with bulbar symptoms, which include dysarthria, dysphagia 
and fatigable chewing. Fewer than 5 percent present with proximal limb weakness 
alone (Bird et al., 2014). A myasthenic crisis occurs when muscles that control 
breathing weaken to the point that ventilation is inadequate, creating a medical 
emergency and requiring assisted ventilation. In individuals whose respiratory muscles 
are affected by their disease, a crisis may be triggered by infection, fever, surgery, 
emotional stress or an adverse reaction to medication (Téllez-Zenten et al., 2004). 
 
1.1.4. Epidemiology  
Although MG is rare, prevalence rates for MG have increased over time, possible 
due to improvements in diagnosis. Recent prevalence rates approach 20/100 000. The 
onset of MG is influenced by gender and age in a bimodal fashion. In patients younger 
than 40, women predominate with a ratio of 7:3. In the fifth decade, new cases of MG 
are evenly distributed between men and women. After age 50, new cases of MG are 
slightly more common in men with a ratio of 3:2 (reviewed by Juel and Massey, 2007). 
 
1.1.5. Therapeutic 
Treatment of MG is based on four different options which take different amounts of 
time before muscular weakness will improve (Fig. 1): 
 
 Improvement of neuromuscular transmission by acetylcholinesterase inhibitors, 
e.g. pyridostigmine, neostigmine and physostigmine; 
 
 Treatment of acute exacerbations (plasmapheresis, immunoadsorption, 
intravenous immunoglobulin); 
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 Immunosuppression, e.g. corticosteroids, azathioprine and monoclonal 
antibodies 
 
 Thymectomy. 
 
 
           Fig. 1 - Onset of action of the different therapy options in myasthenia (adapted from Sieb, 2014). 
 
Therapy usually begins with acetylcholinesterase inhibitors. Acetylcholinesterase 
inhibitors slow the hydrolysis of ACh at the neuromuscular junction and provide 
temporary improvement in strength in many patients with MG but do not retard the 
underlying autoimmune attack on the neuromuscular junction. Corticosteroids are the 
most widely used immune modulating agents for MG. Although the mechanism of 
action in MG is unknown, corticosteroids have numerous effects on the immune system 
including reduction of cytokine production. Azathioprine is an effective agent for long-
term immune modulation in MG as a steroid sparing drug or as initial immunotherapy. 
Compared to corticosteroids, azathioprine has a favorable side effect profile for long 
term use (reviewed by Juel and Massey, 2007).  In some situations, plasma exchange 
can be used in MG to achieve rapid, temporary improvement in strength. During 
plasma exchange, plasma containing nAChR antibodies is separated from whole blood 
and replaced by albumin or fresh frozen plasma. Also, intravenous immunoglobulins 
(IVIg) can be used to bind the circulating antibodies. Thymectomy has also been widely 
performed in an effort to achieve medication-free remission in MG. However, and 
because of the increased surgical risk and reduced life span, thymectomy is rarely 
performed in MG patients nowadays. For each patient, an individual treatment plan 
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must be compiled that will be adjusted further on the therapeutic response during the 
course. Using the spectrum of treatment options available nowadays, the majority of 
myasthenic patients can have largely normal lives. Since these therapies have quite 
short-term benefits (reviewed by Juel and Massey, 2007), it is critical to find new 
therapeutic strategies with less side effects. The overall goal is to reestablish normal 
clinical neuromuscular function while minimizing adverse side effects. 
 
1.2. Animal models to study Myasthenia gravis 
Animal models allow a better understanding of the pathophysiological processes of 
human diseases. It is important to have in mind the similarities and the differences of 
the species chosen, and the resemblance pathology and outcome of an induced 
disease or disorder in the model species, with the respective lesions of the target 
species, so the experimental results can be extrapolated from one species to the other 
(Hau and Van Hoosier, 2003). Few induced models completely mimic the target 
disease in Human’s (Hau and Van Hoosier, 2003). Patrick and Lindstrom in 1973 
immunized rabbits in order to obtain autoantibodies against the recently purified AChR, 
and observed that the animals developed weakness and electrophysiological 
abnormalities that were similar to those in human MG (Patrick and Lindstrom 1973). 
This experimental disorder in rabbits, received lately the name Experimental 
Autoimmune Myasthenia Gravis (EAMG). Later EAMG was reproduced in other 
species (Lennon et al., 1975) and has contributed with a great deal of information for 
unveiling the molecular and immunological features of this disease. There are 
numerous procedures to create an animal model for MG. A very common one, which 
recreates most of the observed symptoms of MG in Humans, consists on injecting 
rodents with anti-nAChR Abs and/or their immunization with nAChRs isolated from 
Torpedo californica (Aricha et al., 2006). Baggie and collaborators showed that the 
breaking of tolerance to a single T cell epitope of the self-autoantigen induces 
autoreactive T cells and specific Abs to rat AChR (Baggi et al., 2004). This model was 
established by immunizing a susceptible rat strains (Lewis rats) with a synthetic peptide 
corresponding to region α97-116 of the rat AChR α subunit, in CFA (Complete 
Freund’s Adjuvant – a mixture of oils and water plus killed Mycobacterium tuberculosis 
strain, used to stimulate immune response). This model of EAMG is valid as a model to 
understand the key immunological processes and molecular aspects, leading to MG as 
well as providing a practical instrument for testing the capability of possible treatment 
methods for MG and other antibody-mediated autoimmune diseases (Baggi et al., 
2012).  
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However, experimental MG differs from human disease in a few features (Table 1).  
Despite, myasthenic patients commonly present thymic alterations, suggesting a 
potential role of the thymus in the pathogenesis of the disease (Meinl et al., 1991), 
induced animals develop EAMG after AChR-immunization and the auto-sensitization 
process seems to occur only in draining lymph nodes (Christadoss et al., 2000), 
apparently without affecting the thymus, as in MG patients. 
 
 
Table 1 - Similarities and differences between MG and EAMG (Adapted from Baggi et al., 2012). 
Similarities Differences 
Immunopathological features 
Presence of anti-AChR Abs in the 
serum; 
  
Deposits of IgGs and C3 complement 
component at the NMJ; 
  
Loss of muscle nAChRs; 
  
MHC class II-restricted presentation of 
AChR epitopes; 
  
Involvement of T helper cells in B -
cell antibody production. 
Disease does not arise 
spontaneously in animals,  needs  for 
induction factors; 
Involvement of the thymus (present 
in some cases of MG, absent in 
EAMG). Thymic alterations are absent 
in EAMG, and    in MG patients, 
hypertrophy and thymomas are often 
present; 
Phagocytic cells detected in the 
acute phase of rat EAMG, are absent at 
the NMJ of human MG patients. 
Clinical manifestations 
Muscle weakness, most prominent in 
the upper body; 
Decreased response in the repetitive 
nerve stimulation test; 
Reduction in the miniature end-plate 
potential amplitude; 
Temporary improvement in muscle 
strength after anti-AChE treatment 
(Tensilon test). 
 Absence of ocular signs; 
  
Absence of relapse and remission 
periods. 
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1.3. The neuromuscular junction: Structure and function 
The terminal arborization of α–motor neuron axons from the ventral horns of the 
spinal cord and brainstem provides the nerve terminals that form the NMJ (Fig. 2). 
These myelinated axons reach the muscles through peripheral nerves; then each axon 
divides into branches that innervate many individual muscle fibers (Conti-Fine et al., 
2006). Neuromuscular transmission at the skeletal muscle occurs when a quantum of 
ACh from the nerve ending is released and binds to the nAChRs on the postjunctional 
muscle membrane. The nerve terminal contains synaptic vesicles (SVs), each of which 
contains 5000–10 000 molecules of ACh (Hirsch, 2007). The content of a single vesicle 
is referred to as a ‘quantum’ of the transmitter. Occasional spontaneous release of 
quanta of ACh results in the production of a so-called miniature endplate potential 
(mepp) at the postsynaptic membrane. The arrival of the action potential at the nerve 
terminal results in opening of the voltage-gated calcium (P/Q and possibly N-type) 
channels (Hirsch, 2007), which are arranged in regular parallel arrays at the active 
zones. When the nerve action potential reaches the synaptic boutons, the 
depolarization opens voltage-gated Ca2+ channels on the presynaptic membrane. This 
Ca2+ influx triggers fusion of synaptic vesicles with the presynaptic membrane and ACh 
release. The ACh diffuses into the synaptic cleft where it can be hydrolyzed by AChE 
or binding to nAChR. The binding of ACh to postsynaptic nAChR thereby triggers the 
influx of Na+ through nAChR channel pore into the muscle fiber. The resulting endplate 
potential (EPP) activates voltage-gated Na+ channels, leading to further influx of Na+ 
and spreading of the action potential along the muscle fiber (Conti-Fine et al., 2006).  
The postsynaptic transmembrane protein, muscle-specific tyrosine kinase (MuSK) 
(Fig. 2), can be also an autoantigen in some MG patients (Hoch et al., 2001). MuSK 
expression in both developing and mature muscle is similar to that of nAChR. In mature 
muscle, MuSK is present prominently only at the NMJ, where it is part of the receptor 
for agrin. Agrin is a protein synthesized by motor neurons and secreted into the 
synaptic basal lamina. The signaling mediated by agrin/MuSK interaction triggers and 
maintains rapsyn-dependent clustering of nAChR and other postsynaptic proteins 
(Ruegg and Bixby, 1998). Rapsyn, a peripheral membrane protein exposed on the 
cytoplasmic surface of the postsynaptic membrane, is necessary for clustering of 
nAChR, with which it coclusters. Rapsyn and AChR are present in equimolar 
concentrations at the NMJ, and they may be physically associated. Rapsyn causes 
clustering of NMJ proteins other than the nAChR, including MuSK. Mice lacking agrin 
or MuSK fail to form NMJs and die at birth of profound muscle weakness, and their 
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AChR and other synaptic proteins are uniformly expressed along the muscle fibers 
(Glass et al., 1996). 
 
Fig. 2 - Structure of the NMJ (adapted from Conti-Fine et al., 2006). 
 
1.3.1. NMJ properties that influence susceptibility to muscle weakness 
in MG 
The EPP generated in normal NMJs is larger than the threshold needed to 
generate an action potential. This difference may vary in different muscles, as 
discussed below. Neuromuscular transmission safety factor is defined as the ratio 
between the actual EPP and the threshold potential required to generate the muscle 
action potential. Its reduction is the electrophysiological defect that causes MG 
symptoms (Conti-Fine et al., 2006). Also, the postsynaptic folds (Fig. 2) form a high-
resistance pathway that focuses endplate current flow on voltage-gated Na+ channels 
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in the depths of the folds, thereby enhancing the safety factor. A reduction in the 
number or activity of the nAChR at the NMJ decreases the EPP, which may still be 
adequate at rest.  However, when the quantal release of ACh is reduced after repetitive 
activity, the EPP may fall below the threshold needed to trigger the action potential 
(Conti-Fine et al., 2006). NMJ properties vary among muscles and may influence 
muscle susceptibility to MG (Hughes et al., 2006). This is well illustrated by the NMJ of 
the extraocular muscles (EOMs), which are especially susceptible to developing 
myasthenic weakness. The NMJs of EOMs differ from those of skeletal muscle in 
several ways. They have less prominent synaptic folds, and therefore fewer 
postsynaptic nAChRs and Na+ channels, and a reduced safety factor (Khanna and 
Porter, 2002). They are subject to very high neuronal firing frequency, making them 
prone to fatigue. Also, they express less intrinsic complement regulators, making them 
more susceptible to complement-mediated injury (Kaminski et al., 2004). In skeletal 
muscles, fast twitch fibers have NMJs with greater quantal contents, a greater degree 
of postsynaptic folding (Wood and Slater, 1997), and higher postsynaptic sensitivity to 
ACh than slow-twitch NMJs (Sterz et al., 1983), and they have increased Na+ current 
in the NMJ region (Ruff, 1996). These properties may make fast-twitch skeletal 
muscle fibers less susceptible to myasthenic failure than slow-twitch fibers. 
 
1.4. Purinergic receptor subtypes 
The potent actions of extracellular ATP on many different cell types implicates the 
action of membrane receptors (Burnstock, 2007). Purinergic receptors were first 
defined in 1976 (Burnstock, 1976), and 2 years later a basis for distinguishing two 
types of purinoceptor, identified as P1 and P2 (for adenosine and ATP/ADP, 
respectively), was proposed (Burnstock, 1978). Later the P2 receptors were subdivided 
into P2X (ionotropic) and P2Y (metabotropic) subtypes on the basis of its 
pharmacological profile (Burnstock and Kennedy, 1985; Abbracchio et al., 2006; 
Abbracchio et al., 2009; Burnstock, 1976).  
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Fig. 3 - The purinergic receptor family. Extracellular ATP is the agonist of both P2X and P2Y receptors and is also the substrate of 
ectonucleotidases, which degrade ATP to adenosine and transiently generate ADP, providing the agonist for P2Y receptors. 
Adenosine, the final product of adenine nucleotide hydrolysis, activates P1 or adenosine receptors (Adapted from Baroja-Mazo et 
al., 2013).   
 
1.5. ATP on neuromuscular transmission 
Over 30 years ago, it was demonstrated that adenosine 5′-triphosphate (ATP) is 
released from the motor nerve endings in the neuromuscular junction along with the 
major transmitter acetylcholine (ACh) (Silinsky, 1975). Released ATP modulates 
neuromuscular transmission either by directly activating P2 purinoceptors (P2R) 
(Salgado et al., 2000) or indirectly through the activation of P1 receptors after being 
metabolized into adenosine (ADO), via ecto-nucleotidases pathway (Cunha et al., 
1996a).  
 
1.5.1. Ectonucleotidases 
Endogenous purine nucleotides (ATP, ADP, and AMP) released into the  
extracellular space may be converted ultimately to adenosine through a variety of cell  
surface-located enzymes referred to as ectonucleotidases. Within the past decade, 
ectonucleotidases belonging to several enzyme families have been discovered, cloned  
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and characterized. There are four major families of ectonucleotidases, namely the  
ectonucleotide triphosphate diphosphohydrolases (E-NTPDase, hydrolysing  
extracellular nucleoside tri- and diphosphates, but not monophosphates), comprising  
four surface-located different members (E-NTPDase 1,2,3 and 8), among which the 
ENTPDase1 is also called CD39; the ectonucleotide pyrophosphatase/ 
phosphodiesterase (E-NPP) family that can hydrolyse pyrophosphate 5’-monodiester  
bonds in ATP and dinucleoside polyphosphates or artificial substrates, comprising  
three different members (E-NPP1,2,3), among which the E-NPP3 is also called CD203; 
the ecto-5’-nucleotidase also called CD73, which hydrolyses only nucleosides  
monophosphates; finally, the alkaline phosphatases (AP) non-specific  
phosphomonoesterases, comprising five isoforms in the mouse, only one of which is 
expressed in the mammalian brain, which release inorganic phosphate from nucleoside 
5’-tri-, 5’-di- and 5’-monophosphates (Zimmerman, 1996; reviewed by Noji et al., 2004). 
The role of ectonucleotidases in synaptic transmission may be functionally relevant. 
They inactivate the released nucleotides and, thus, limit its temporal and spatial action. 
In situ the activity of ectonucleotidases is controlled by the substrate availability 
(Robson et al., 2006). CD39 and CD73 are two major ectoenzymes that sequentially 
hydrolyze adenine nucleotides, leading to adenosine generation. CD39 hydrolyzes both 
ATP and ADP to AMP, which is subsequently converted to adenosine through CD73, a 
glycosyl phosphatidylinositol (GPI)-anchored molecule (Zimmermann, 1992). The 
ectonucleotidase pathway is regulated at the limiting step catalyzed by the CD73. This 
enzyme is subjected to feed-forward inhibition by ATP and/or ADP (Magalhães-
Cardoso et al., 2003). The extracellular ATP hydrolysis at NMJs shares many 
similarities with that described in many different preparations, being mainly catalysed 
by ectonucleotidases to form adenosine (Cunha, 2001). The main difference found in 
NMJs is the presence of an ecto-AMP deaminase activity that converts AMP into IMP 
(Cunha and Sebastião, 1991; Magalhães-Cardoso et al., 2003). Indeed skeletal 
muscles fibers are one of the mammalian tissues with higher activity of AMP 
deamination (Ogasawara et al., 1974; Magalhães-Cardoso et al., 2003). Most of this 
enzymatic activity is associated with muscle fibers, but it has been shown that AMP 
deaminase is also present in the vicinity of neuronal and circulatory elements 
(Thompson et al., 1992). Magalhães-Cardoso and colleagues (2003) have presented 
evidences demonstrating that ecto-AMP deaminase blunts the ATP-derived adenosine 
A2A receptor facilitation of ACh release at rat motor nerve endings (Correia-de-Sá et al., 
1991; reviewed by Ribeiro et al., 1996). 
 
11 FCUP/ICBAS 
Introduction 
 
 
 
Fig. 4 - Extracellular catabolism of adenine nucleotides and nucleosides at the rat motor nerve terminals. The numbers in the figure 
represent: 1- ecto-5′-nucleotidase; 2- ecto-AMP deaminase; 3- ecto-adenosine deaminase; 4- adenosine transporter (adapted from 
Magalhães-Cardoso et al., 2003). 
 
1.5.2. ATP receptors activation – P2 receptors 
Adenosine triphosphate (ATP) accumulates in the synaptic cleft of the 
neuromuscular junction (NMJ) during synaptic transmission due to the release of 
approximately equal quantities (Santos et al., 2003) of ATP from nerve terminals 
(Cunha and Sebastião, 1991; Silinsky et al.,1999; Vizi et al., 2000) and stimulated 
muscle fibres (Vizi et al., 2000). This ATP does not appear to affect muscle fibres 
(Henning, 1997) but does influence the release of ACh (and co-released ATP) at the 
NMJ (Ribeiro and Walker, 1975). However, both enhancement (Salgado et al., 2000) 
and reduction (Silinsky et al., 1999) of neurotransmitter release by ATP have been 
reported. A possible explanation for the contrasting effects of ATP on neurotransmitter 
release at the NMJ is that it may act directly on ionotropic P2X receptors and/or 
metabotropic P2Y receptors, or indirectly via its metabolite adenosine on other 
metabotropic receptors (Ralevic and Burnstock, 1998). P2 receptors are activated by 
purines and some subtypes also by pyrimidines. Extracellular nucleotides act through 
purinergic receptors that comprise seven distinct P2X receptor subtypes (P2X1–7), 
which act as ion channels, and eight P2Y receptor subtypes (P2Y1, P2Y2, P2Y4, P2Y6, 
P2Y11–14) that are G protein coupled receptors (GPCRs) (Ralevic and Burnstock,1998).  
 
Members of the existing family of ligand-gated nonselective cation channel P2X1–7 
receptor subunits show a subunit topology of intracellular -NH2 and -COOH termini 
possessing consensus binding motifs for protein kinases; two transmembrane-
spanning regions (TM1 and TM2).  The TM1 is involved in the channel gating 
properties and the TM2 is associated to the ion pore.  A large extracellular loop, with 10 
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conserved cysteine residues forming a series of disulfide bridges; hydrophobic H5 
regions close to the pore vestibule, for possible receptor/channel modulation by cations 
(magnesium, calcium, zinc, copper, and proton ions); and an ATP-binding site, which 
may involve regions of the extracellular loop adjacent to TM1 and TM2 (Fig. 5B). The 
P2X1–7 receptors show 30–50% sequence identity at the peptide level. The 
stoichiometry of P2X1–7 receptor subunits is thought to involve three subunits that form 
a stretched trimer (Khakh et al., 2001). It has become apparent that the pharmacology 
of the recombinant P2X receptor subtypes expressed in oocytes or other cell types is 
often different from the pharmacology of P2X receptor-mediated responses in naturally 
occurring sites. This is partly because heteromultimers as well as homomultimers are 
involved in forming the trimer ion pores. Spliced variants of P2X receptor subtypes 
might play a part (Chen et al., 2000). For example, a splice variant of the P2X4 
receptor, while it is nonfunctional on its own, can potentiate the actions of ATP through 
the full-length P2X4 receptors (Townsend-Nicholson et al., 1999). Third, the presence 
in tissues of powerful ectoenzymes that rapidly break down purines and pyrimidines is 
not a factor when examining recombinant receptors, but is in vivo. P2X7 receptors are 
predominantly localized on immune cells and glia, where they mediate proinflammatory 
cytokine release, cell proliferation, and apoptosis. P2X7 receptors, in addition to small 
cation channels, upon prolonged exposure to high concentrations of agonist, large 
channels, or pores are activated that allow the passage of larger molecular weight 
molecules. The possible mechanisms underlying the transition from small to large 
channels have been considered (Egan et al., 2006). The P2X receptor family shows 
many pharmacological and operational differences (Gever et al., 2006). The kinetics of 
activation, inactivation, and deactivation also vary considerably among P2X receptors. 
The best characterized mechanism underlying the activity of these receptors result 
from their high permeability for Ca2+. Activation of P2X receptors induces an increase in 
intracellular Ca2+ and depolarization wave, which leads to signal transmission. 
Functional interactions with other ion channels, K+ outflow and Na+ influx are also 
involved in P2X receptors signaling (Khakh and North, 2012). 
 P2X7 was the ﬁrst P2 receptor to be identiﬁed at the neuromuscular junction, 
although ATP and its metabolites ADP and adenosine have long been known to affect 
synaptic transmission at the NMJ (Fu and Poo, 1991). P2X7 receptor subunits are 
present at all NMJs in a wide variety of skeletal muscles studied from birth into 
adulthood (Moores et al., 2005). 
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Metabotropic P2Y receptors (P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13, and 
P2Y14) are characterized by a subunit topology of an extracellular -NH2 terminus and 
intracellular -COOH terminus, the latter possessing consensus binding motifs for 
protein kinases; seven transmembrane-spanning regions, which help to form the 
ligand-docking pocket; a high level of sequence homology between some 
transmembrane-spanning regions, particularly TM3, TM6, and TM7; and a structural 
diversity of intracellular loops and COOH terminus among P2Y subtypes, so influencing 
the degree of coupling with Gq/11, Gs, Gi, and Gi/o proteins (Abbracchio et al., 2006) 
(Fig. 5C). Each P2Y receptor binds to a single heterotrimeric G protein (Gq/11 for 
P2Y1,2,4,6), although P2Y11 can couple to both Gq/11, and Gs, whereas P2Y12 and 
P2Y13 couple to Gi and P2Y14 to Gi/o. Many cells express multiple P2Y subtypes 
(Abbracchio et al., 2006 and Volonté et al., 2006). P2Y receptors show a low level of 
sequence homology at the peptide level (19–55% identical) and, consequently, show 
significant differences in their pharmacological and operational profiles. Some P2Y 
receptors are activated principally by nucleoside diphosphates (P2Y1,6,12), while others 
are activated mainly by nucleoside triphosphates (P2Y2,4). Some P2Y receptors are 
activated by both purine and pyrimidine nucleotides (P2Y2,4,6), and others by purine 
nucleotides alone (P2Y1,11,12). In response to nucleotide activation, recombinant P2Y 
receptors either activate phospholipase C (PLC) and release intracellular calcium or 
affect adenylyl cyclase and alter cAMP levels (Burnstock, 2007). 
Recent evidence suggests that ATP can play a role in forming and maintaining the 
postsynaptic specializations by activating its corresponding receptors (Tsim and 
Barnard, 2002). 
Several lines of evidence support the co-existence and co-activity of P2Y1 and 
P2Y2 receptors at the NMJS (Choi et al., 2001). The co-localization of these two P2Y 
receptors at the NMJ has now been observed in the four diverse species so far 
examined, i.e., mouse, rat, a bird, and an amphibian (Choi et al., 2001), suggesting that 
it has a distinct significance in muscle function. 
De Lorenzo and colleagues (2006), demonstrated that, at the mouse 
neuromuscular junction, extracellular ATP induced presynaptic inhibition of 
spontaneous ACh release via activation of P2Y receptors.  
Recently, Giniatullin and colleagues (2015), revealed key steps in the purinergic 
control of synaptic transmission via P2Y12 receptors associated with lipid rafts, and 
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identified NADPH oxidase as the main source of ATP-induced inhibitory ROS at the 
neuromuscular junction. 
 
 
 
 
 
Fig. 5 - Membrane receptors for extracellular adenosine and ATP.  A- The P1 family of receptors for extracellular adenosine are 
G protein-coupled receptors (S-S; disulfide bond). B- The P2X family of receptors are ligand-gated ion channels (S-S; disulfide 
bond; M1 and M2, transmembrane domains). C- The P2Y family of receptors are G protein-coupled receptors (S-S; disulfide bond; 
green circles represent amino acid residues that are conserved between P2Y1, P2Y2, and P2Y6 receptors; fawn circles represent 
residues that are not conserved; and red circles represent residues that are known to be functionally important in other G protein-
coupled receptors). D- Predicted membrane topography of ectonucleotidases, consisting of the ectonucleoside triphosphate 
diphosphohydrolase (E-NTPDase) family, the E-NPP family, alkaline phosphatases, and ecto-5′-nucleotidase (adapted from 
Burnstock, 2007). 
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2. Adenosine as a neuromodulator 
Adenosine (ADO) is a ubiquitous molecule and an essential component of all living 
cells. This nucleoside is involved in key processes of the primary metabolism, 
especially the metabolism of nucleotides, nucleosides and amino acids that have 
sulfide groups and in the modulation of cellular metabolic state (e.g. transmethylation 
reactions and ammonia processing) (Cunha, 2001; Cunha, 2005; Stone, 1985). The 
first description that suggests that ADO and its precursor, adenosine triphosphate 
(ATP) could affect neuronal function has been advanced by Drury and Szent-Gyorgyi 
(1929). Later studies in the neuromuscular junction (Ginsborg and Hirst, 1972; Ribeiro 
and Walker, 1973) and cortical neurons (Phillis et al., 1974) have shown that actually 
ADO plays a neuromodulatory role. ATP is stored in synaptic vesicles and can also be 
released by nerve terminals during depolarization (Zimmermann, 1994). Previous 
studies using NMJs from different species reported that nerve stimulation triggers the 
release of ATP from the motor nerve terminal to the synaptic cleft (Magalhães-Cardoso 
et al., 2003; Santos et al., 2003).  Most commonly, ATP co-released with ACh from 
motor nerve terminals is metabolized extracellularly via the ecto-nucleotidase pathway 
that sequentially catabolizes ATP into AMP and then into ADO through the action of an 
ecto-5’nucleotidase (Magalhães-Cardoso et al., 2003), which is feed-forwardly inhibited 
by ATP and/or ADP (Cunha et al., 1996a). Interestingly, at the NMJ, AMP can be 
alternatively deaminated into the inactive metabolite, IMP through the action of 5’AMP-
deaminase at the rat NMJ, thus bypassing ADO formation (Magalhães-Cardoso et al., 
2003). Moreover, ADO can either be released as such, from activated nerve terminals, 
Schwann cells and activated muscle fibers (reviewed in Cunha, 2005).  Although there 
are no evidences of accumulation of ADO in synaptic vesicles or the release of this 
molecule as a quantum, the presence and accumulation of extracellular ADO in the 
synapses is related to the release of neurotransmitters and also with the frequency and 
intensity of neuronal firing (reviewed in Cunha, 2005). Cunha et al., (1996a) and 
Wieraszko and Seyfried (1989) demonstrated that ATP release is greater the higher 
the frequency of nerve stimulation and the contribution of ADO derived from ATP 
increases by enhancing frequency nerve stimulation. On the other hand, the 
contribution of ADO released through equilibrative nucleoside transporters is 
predominant at lower nerve stimulation frequencies (Correia-de-Sá et al., 1996; Cunha 
et al., 1996b). In basal conditions, the intracellular concentration of ADO is typically 
around 10-50 nM in the cell types where it was so far quantified.  When intracellular 
levels of ADO exceed its extracellular concentration, for example under stressful 
situations where the exacerbation of intracellular ATP consumption exceeds its 
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capacity of rephosphorylation, transport through equilibrative nucleoside transporters is 
reversed, i.e., there is an increase in the extracellular ADO (Geiger and Fyda, 1991). 
Extracellular adenosine can be inactivated by cellular uptake through the equilibrative 
nucleoside transporters (Geiger and Fyda, 1991) or by deamination to inosine by 
adenosine deaminase (ADA) (Correia-de-Sá and Ribeiro, 1996). The extracellular 
adenosine is able to act on metabotropic adenosine receptors located in the cell 
membrane of neighbouring cells (as well as of the cell that released adenosine).  The 
activation of the different types of adenosine receptors can then modify cell metabolism 
according to the set-up of ADO receptors and to the primary metabolism of each 
particular cell type (Cunha, 2005). Although ADO does not meet all the requirements to 
be considered a neurotransmitter, it is able to modulate the activity of the nervous 
system at a presynaptic level, exerting its action through its specific receptors (Correia-
de-Sá et al., 1996; Cunha, 2001).   
 
2.1. Adenosine receptors activation – P1 receptors 
ADO as a neuromodulator mediates its physiological effects via cell surface 
receptors. ADO receptors have seven putative transmembrane (TM) domains and are 
coupled to heterotrimeric G proteins. There are four types of metabotropic receptors, 
denominated as A1, A2A, A2B and A3 receptors (Fredholm et al., 2001). A1 and A3 
receptors are coupled to Gi/o inhibitory proteins, while A2A and A2B are coupled to Gs 
excitatory proteins (Linden, 2001 and Ribeiro et al., 2003). The binding of ADO to its 
receptor triggers a series of signal transduction mechanisms that are initiated by the 
receptor associated G proteins (Figure 6). ADO action depends on the receptor 
density, affinity and location, and in general the agonist is more efficient, when higher 
densities of the receptors are present. Therefore, low endogenous ADO levels, the 
ones observed under basal conditions, have the potential to activate the receptors only 
when they are in higher numbers, and not when these receptors are sparse (Fredholm 
et al., 2001). At the rat NMJ, high-affinity A1 and A2A receptors are responsible for the 
major effects exerted by the ADO, namely at modulating synaptic transmission. Co-
existence of both inhibitory A1R and facilitatory A2AR on the same nerve terminal was 
first proved using neurochemical and electrophysiological methods at the rat NMJ 
(Correia-de-Sá et al., 1991); later on it was shown that ADO could facilitate the release 
of neurotransmitter via activation of cAMP-coupled A2AR (Correia-de-Sá and Ribeiro 
1994). The dual modulatory role of ADO via presynaptic inhibitory A1R and facilitatory 
A2AR is highly dependent on the nerve stimulation pattern (Correia-de-Sá et al., 1996), 
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particularly when this nucleoside is build-up from the catabolism of ATP release 
(Magalhães-Cardoso et al., 2003). The tonic inhibitory effect mediated by A1R, is 
observed at low frequency stimulation under resting conditions, where low amounts of 
ADO activate predominantly inhibitory A1R. High-frequency, high-intensity motor nerve 
stimulation potentiates the tonic adenosine A2AR-mediated facilitation of ACh release, 
due to accumulation of ADO in the synaptic cleft, which may overcome muscular 
tetanic fade, whereas activation of the inhibitory A1R becomes less effective (Correia-
de-Sá et al., 1996). During 50 Hz-trains, ATP is able to reach high levels, enough to 
inhibit CD73. Interburst intervals, allows the recovery from CD73 enzymatic inhibition, 
because there is a delayed burst-like formation of ADO, leading to high synaptic 
concentrations of ADO, similar to those required to promote the activation of A2AR 
(Correia-de-Sá et al., 1996). A2AR act via subtle modifications of the presynaptic inter-
receptor dynamics (Sebastião and Ribeiro, 2000) involving the generation of 
intracellular second messengers, such as cAMP (Correia-de-Sá and Ribeiro 1994) and 
Ca2+ (Correia-de-Sá et al., 2000). It worth noting that fine-tuning control of facilitatory 
nAChRs containing α3β2 subunits (Faria et al., 2003) and muscarinic M1 and M2 
(Oliveira et al., 2002) receptors, is mediated by endogenous ADO. In parallel, there is a 
co-ordinate shift in Ca2+ cell dynamics operating ACh exocytosis, from the prevalent 
P/Q-type to the “facilitatory” L-type channel, in a way completely reversed by blocking 
A2AR activation (Oliveira et al., 2004). These mechanisms represent a novel form of 
synaptic plasticity mediated by ADO and may function to overcome neuromuscular 
tetanic depression during neuronal firing. Neurotransmission failure in MG is 
particularly evident during intense motor nerve activity, a situation where ADO, acting 
via A2AR, has a key role by promoting increases in the safety margin of NMT (Correia-
de-Sá and Ribeiro 1996). Recently, our group demonstrated that A2AR fine-tuning 
control of NMT is impaired in animals models of MG (Noronha-Matos et al., 2011; 
Oliveira et al., 2015a). This seems to be mainly due to a decrease in endogenous ADO 
levels, leading to a reduction on tonic A2AR activity, which can be functionally recovered 
by application of the ADO precursor, AMP (Noronha-Matos et al., 2011; Oliveira et al., 
2015a).  
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Fig. 6 - Signal transduction pathways associated with the activation of the human adenosine receptors (adapted from  Moro et al., 
2005). 
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3. AIM 
Recently, our group demonstrated that endogenous ADO accumulation in 
myasthenic motor endplates is insufficient to sustain transmitter release demand 
through tonic activation of presynaptic facilitatory A2AR (Noronha-Matos et al., 2011; 
Oliveira et al., 2015a). Considering that A2AR is preferentially activated by ADO 
originated from the catabolism of released adenine nucleotides catalysed by ecto-5’-
nucleotidase/CD73 (Cunha et al., 1996a) and that imparement of ADO tone regulating 
neurotransmitter release at the motor endplate is not associated with deficiencies in the 
activity of this enzyme (Oliveira et al., 2015a), one may speculate about deficts 
occurring in the release of ATP or in its extracellular metabolism by NTPDases 
upstream ultimate ADO formation by the ecto-5’-nucleotidase/CD73.  
In this context we decided to quantify the amount of nerve-evoked ATP released 
from motor endplates and to evaluate the kinetics of the extracellular metabolism of 
ATP at phrenic nerve-hemidiaphragm preparations from EAMG animals. 
As previously mentioned, motor nerve terminals are equipped with ATP-sensitive 
P2R in addition to P1 ADO receptors. It, thus, might happen that released ATP may 
undertake a role of its own to control neuromuscular transmission independently of its 
role as a source of ADO, but this has never been investigated in EAMG animals. 
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4. Materials and methods 
4.1. Induction and clinical assessment of Experimental Autoimmune 
Myasthenia gravis (EAMG) rat models 
Female rats (Wistar Han, 100 g) (Charles River, Barcelona, Spain) were kept at a 
constant temperature (21ºC) and a regular light (07.00h–19.00h)–dark (19.00h 
07.00hh) cycle, with food and water ad libitum and randomly divided into three groups. 
Under general anesthesia, with ketamine (75 mg/kg) and medetomidine (100mg/kg) by 
intraperitoneal administration (Oliveira et al., 2015a) for the EAMG model, the rats were 
anaesthetized and immunized subcutaneously at four sites (two hind footpads and 
shoulders) with 50 μg of R97-116 peptide (DGDFAIVKFTKVLLDYTGHI, JPT Peptide 
Technologies GmbH) – a synthetic peptide that corresponds to a specific region on the 
α subunit of the rat nicotinic AChR – in CFA (Complete Freund’s Adjuvant) (Sigma, St. 
Louis, MO, USA), on day 0 and were then submitted to a second boost on day 30 with 
the same peptide in IFA (Incomplete Freund’s Adjuvant) (Baggie et al., 2004; Oliveira 
et al., 2015a). The control group was immunized with CFA and IFA emulsions, at the 
same time as the EAMG models, but instead of nAChR R97-116 peptide they were 
injected with phosphate-buffered saline (PBS). The naive group animals were not 
submitted to any kind of treatment. Evaluation of disease manifestations in immunized 
rats was performed by testing muscular weakness. Clinical scoring was based on the 
presence of tremor, hunched posture, general behavior, fatigability and the overall 
appearance of the animal. Disease severity was graded as follows: grade 0, normal 
strength and no fatigability; grade 1, mildly decreased activity and weak grip or cry; 
grade 2, clinical signs present at rest; grade 3, severe clinical signs at rest, no grip, 
moribund; and grade 4, dead (Baggi et al., 2004). Each animal was weighed and 
evaluated for disease manifestation twice weekly until euthanized by decapitation 
(Baggi et al., 2004). Animal handling and experiments were in accordance with the 
guidelines prepared by Committee on Care and Use of Laboratory Animal Resources 
(National Research Council, USA) and followed the European Communities Council 
Directive (86/609/ EEC). 
 
4.2. Preparation and experimental conditions  
All animals were euthanized by decapitation, using a guillotine, a fast method, 
which has the advantage of allowing a good exsanguination; this may be required to 
enable the collection of blood samples for subsequent procedures. Then, the animals 
were submitted to surgical isolation of the phrenic nerve hemidiaphragm as described 
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by Correia-de-Sá and Collaborators (1991) (Figure 7). The experiments were 
performed using either left or right phrenic nerve-hemidiaphragm preparations (4-6 
millimeters (mm) width). Each muscle was superfused (5 mL.min−1, 37°C, pH 7.4) with 
gassed (95% O2; 5% CO2) Tyrode’s solution (pH 7.4) containing (mM): NaCl 137, KCl 
2.7, CaCl2 1.8, MgCl2 1, NaH2PO4 0.4, NaHCO3 11.9 and glucose 11.2, at 37ºC 
(Correia-de-Sá et al., 1991). 
 
 
Fig. 7 - Isolated phrenic nerve-hemidiaphragm preparations mounted horizontally in thermostatized organ bathes used to quantify 
the release of [3H]ACh and endogenous ATP. A-Preparations were mounted horizontally across the costal and the tendinous portion 
(phrenic center) with 4 surgical pins. B- Each phrenic nerve was inserted inside a suction electrode manufactured in the Laboratory 
used to promote phrenic nerve electrical stimulation.  
 
4.3. [3H]ACh release experiment from phrenic nerve 
hemidiaphragm preparations 
The procedures used for labeling the preparations and measuring evoked [3H]-
acetylcholine ([3H]ACh) release, have been previously described (Correia-de-Sá et al., 
1991). Briefly, phrenic nerve-hemidiaphragm preparations were mounted in 3-mL 
 A 
 B 
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capacity Perspex chambers heated to 37ºC. After a 30 min equilibration period, the 
perfusion was stopped and the nerve terminals were labeled for 40 min with 1µM [3H]-
choline (specific activity 2.5 µCi/nmol) under electrical stimulation, at a frequency of 1 
Hz (0.04ms duration, 8mA). The phrenic nerve was stimulated with a glass–platinum 
suction electrode, placed near the first division branch of the nerve trunk, to avoid 
direct contact with muscle fibres (Figure 8). After the labeling period, the preparations 
were again superfused (37.5 mL/min) and the nerve stimulation ceased. From this 
point onwards, hemicholinium-3 (10 µM) was present to prevent the uptake of [3H]-
choline and the synthesis of unlabeled ACh. After a 60 min washout period 1.5 mL, 
bath samples were automatically collected every 3 min using a fraction collector 
(Gilson, FC 203B, France) coupled with a peristaltic pump (Gilson, Minipuls3, France) 
programmed device by emptying and refilling the organ bath with the solution in use. 
The release of [3H]ACh was evoked by two periods of electrical stimulation of the 
phrenic nerve, 5 Hz (750 pulses), starting at min 12 (S1) and min 39 (S2), after the end 
of washout (zero time). Test drugs were added 15 min before S2 and were present up 
to the end of the experiments. Medium incubation aliquots (0.4 mL) were added to 3.5 
mL of Packard Insta Gel II (USA) scintillation cocktail so that tritium content samples 
could be measured by liquid scintillation spectrometry (counting efficiency of 40±2%). 
Radioactivity is expressed as DPM (disintegrations per minute). The evoked release of 
[3H]-ACh was calculated by subtracting the basal tritium outflow from the total tritium 
outflow during the stimulation period (Correia-de-Sá et al., 1996). The change in the 
ratio between the evoked [3H]ACh released during the two stimulation periods (S2/S1), 
relative to the observed in control situations (in the absence of test drugs) was taken as 
a measure of drugs effects. 
 
 
 
 
 
 
 
Fig. 8 - Schematic representation of the experimental procedure for [3H]ACh release experiments. 
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4.4. Release of endogenous ATP from phrenic nerve hemidiaphragm 
preparations 
For ATP release experiments, the innervated hemidiaphragm preparations were 
mounted as described previously for radiochemical experiments. After a 30 min 
equilibration period, the perfusion was stopped and aliquots of 1.5 mL bath samples 
collected automatically every 3 min. Samples were collected for 24 minutes and ATP 
release was induced by electrical stimulation to the time 12 with the frequency of 5Hz 
750 pulses. Two hundred microliter (µL) aliquots were introduced into pre-cooled 
microtubes, which were frozen in liquid nitrogen until analysis The ATP content of the 
samples was evaluated by the luciferin – luciferase ATP bioluminescence assay kit HS 
II (Roche Applied Science, Indianapolis, Indiana). Luminescence was determined using 
a multi detection microplate reader (Synergy HT, BioTek Instruments) (Oliveira et al., 
2015b).  
 
4.5. Kinetic experiments of extracellular catabolism of ATP 
nucleotides and nucleosides  
The extracelular ATP catabolism was evaluated, at 37°C, on phrenic-nerve 
hemidiaphragm preparations from naïve, control, and EAMG rats. After a 30min 
equilibration period, the organ bath was emptied and 2mL of a 30µM ATP in gassed 
Tyrode’s solution was added to the preparations at time zero. Samples of 75µL were  
collected from the bath at diferente times up to 45 min for HPLC with UV detection 
(HPLC-UV, LaChrome Elite, Hitachi, Merck, Germany) analysis of the variation of 
substrate disappearance and product formation (Magalhães-Cardoso et al., 2003; 
Pinheiro et al., 2013). In all experiments, the concentration of products at the different 
times of sample collection was corrected by subtracting the concentration of products 
in samples collected from the same preparation incubated without adding substrate. 
Only IMP, inosine (INO), and hypoxanthine (HX) were spontaneously released from the 
preparations in concentrations that did not exceed 1µM (Magalhães-Cardoso et al., 
2003). There was no spontaneous degradation of ATP at 37°C in the absence of the 
preparation. Concentration of the substrate and products were plotted as a function of 
time (progress curves). The following parameters were analyzed for each progress 
curve: half-life time (t1/2) of the initial substrate, time of appearance of the diferente 
concentrations of the products, and concentration of the substrate.  
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Fig. 9 - Schematic representation of the experimental procedure for the kinetic experiments. 
 
4.5.1. Separation and quantification of ATP nucleotides and 
nucleosides by high-performance liquid chromatography 
(HPLC) analysis 
Separation of ATP and their catabolism products was carried out by ion-pair 
reverse-phase chromatography (IP-RP-HPLC-UV) according to the method described 
by Cascalheira and Sebastian (1992), with minor modifications. The eluent, pH 6.0, 
was composed of (60mM) KH2PO4, (5mM) tetrabutylammonium phosphate and 5-35% 
(v/v) methanol. The elution program was as follows: a linear gradient from 5% to 35% 
(v/v) methanol during 10 minutes followed by a descendent linear gradient over a 
period of 8 minutes for reestablishing the initial elution conditions: absorbance values 
and internal pressure of the system. The mobile phase flow was 1,25 mL/min. 
Chromatographic identification of nucleotides and nucleosides  containing samples was 
performed by comparison with the retention time of high purity standard, separated 
under the same chromatographic conditions. The chromatograms obtained after 25 µl 
solutions injection from standards and samples are shown in figure 10. The 
standards/samples were quantified through the external standard method (Cassiano et 
al., 2009). For each component of the mixture (ATP, ADP, AMP, IMP, ADO, INO, HX) a 
calibration curve was prepared (graph peak area versus concentration) with a linear 
slope within the expected range of concentrations for each compound, and interception 
with the ordinate axis at zero or near zero. The concentration of each compound of the 
sample was determined through the mathematical expression of the straight lines 
calibration (y= mx+b), given that it is proportional to the analytical signal (area) since 
the injected volumes are accurately known. This method requires a strict control of 
technical and instrumental conditions (separation conditions, mobile phase flow, 
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injection volume) to obtain the calibration curves of the compounds (ATP, ADP, AMP, 
IMP, ADO, INO, HX) used in the adenine nucleotides/nucleosides quantification. 
Standard solutions of the compounds were injected (25 μL) with increasing 
concentrations (1.88μM – 30μM), represented in figure 11.  
 
 
 
 
            Fig. 10 - HPLC chromatogram illustrating the separation of ATP nucleotides and nucleosides in standards samples. 
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Fig. 11 - Calibration curves of ATP nucleotides and nucleosides used in this study. 
 
4.6.  Determination half-life time (t1/2)  
The half-life time (t1/2) expresses the period of time required for the amount or 
concentration of the compound to decrease by one-half. 
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When the kinetics is a first-order kinetics, the graphical representation is linear [log 
(concentration) = f (time)].  
 
The mathematical expression of the line is given by the following equation (Shargel and 
Yu, 1980): 
 
 
 
 
 
 
(A-compound concentration; −
𝑘
2,3
  - slope of the straight; A0 - y-axis interception; t - 
time)  
 
The half-life time of this equation results on: 
 
K is a constant expressed as time -1 (k= slope of the straight × 2,3) 
 
 
4.7.  Drugs and Solutions 
ATP; HX; INO; IMP; ADO; AMP; ADP; choline chloride; hemicholinium-3; 
βγimidoATP; CFA, and IFA were obtained from Sigma, St. Louis, MO, USA. The 
scintillation cocktail (Insta – gel Plus) were obtained from Perkin Elmer (Boston, USA); 
R97-116 peptide (DGDFAIVKFTKVLLDYTGHI) was obtained from JPT Peptide 
Technologies GmbH. All stock solutions were stored as frozen aliquots at -20ºC. 
Dilutions of these stock solutions were made daily. 
 
𝑡1/2 =  
0,693
𝐾
 
 
𝑙𝑜𝑔𝐴 = −  
𝐾𝑡
2,3
+ 𝑙𝑜𝑔𝐴0 
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5. Results and discussion 
5.1.  Endogenous release of ATP and its subsequent extracellular 
catabolism at the neuromuscular junction of EAMG animals 
The facilitatory tonus operated by pre-synaptic adenosine A2AR is impaired at motor 
endplates of myasthenic animals (Oliveira et al., 2015a). This seems to be mainly due 
to a decrease in endogenous ADO amounts occurring during neuronal activity, but not 
in resting conditions (Oliveira et al., 2015a), a situation that can be fully reversed by 
incubation of the muscles with the ADO precursor, AMP (Noronha-Matos et al., 2011; 
Oliveira et al., 2015a). It is well established that at the rat neuromuscular junction ADO 
can either be released as such or can be formed from the sequential extracellular 
catabolism of released ATP (Cunha et al., 1996a). In this context we decided to 
evaluate the amount of evoked ATP release from control (CFA) and EAMG animals 
using the luciferin-luciferase bioluminescence assay.  
 
 
 
 
 
 
Fig. 12- A- Time course of ATP release (pmol/mg) quantified in the effluent from phrenic nerve hemidiaphragm preparations of 
CFA and EAMG animals by the luciferin-luciferase assay. The effluent was collected every 3 min during a period of 30 min and the 
phrenic nerve trunk was electrically stimulated with 750 pulses applied at 5 Hz frequency. For the sake of clarity, in the figure it is 
only presented the 3 points before (6’,  9’, 12’) and after (18’,  21’, 24’)  the released period were the evoked released ATP was 
observed (at the period of 15 min incubation) B- Average basal and electrically induced ATP release (pmol/mg) in both CFA and 
EAMG animals.  P*<0,05 (Unpaired Student T’ test) when comparing the average ATP release from EAMG with CFA animals. 
 
The Fig.12A illustrates the time course of endogenous ATP release in both EAMG and 
CFA animals groups. Results shows that ATP release during resting conditions 
remained fairly constant during collection of samples and the values obtained were not 
significantly (P>0.05) different among the two groups, CFA (0,028±0,004 pmol/mg, 
n=6) and EAMG (0,042±0,014 pmol/mg, n=4) (Fig.12B). Phrenic nerve stimulation (750 
pulses delivered at 5 Hz-frequency) elicited the release of ATP above basal levels into 
the bath effluent from both groups of animals. Interestingly, the amount of ATP 
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released from stimulated motor endplates from EAMG animals was significantly 
(P<0.05) higher (0,139±0,039 pmol/mg, n=4) than that obtained in the control (CFA) 
group (0,051±0,006 pmol/mg, n=6) (Fig.12B).   
Although we did not attempted to investigate the origin of ATP released at the 
neuromuscular junction of EAMG animals, one might speculate that it may be 
influenced by the morphological changes occurring at motor endplates of these 
animals, which include a reduction in the total area of nAChR labeling per endplate 
indicating a decrease in the number of effective postsynaptic nAChR (Oliveira et al., 
2015a). In fact, these morphological changes reduce the safety margin of 
neuromuscular transmission and, thus, activation of postsynaptic nAChR, leading to a 
reduced skeletal muscle contractile response in EAMG animals (Oliveira et al., 2015a). 
So, considering that the majority of the ATP release is derived from activated muscle 
fibers and that EAMG animals present a functional impairment on muscle fibers 
activation, it is plausible to hypothesize, that the observed increase in ATP release 
could be originated from the motor nerve terminals compartment.  
On the other hand, increased ATP accumulation at the neuromuscular junction during 
neuronal activity may also result from changes in its extracellular metabolism, which in 
addition to surplus ATP release may increase the quantified levels of the nucleotide. In 
fact, EAMG animals exhibit higher amounts of ATP released from stimulated 
preparations (Fig.12) and the amounts of evoked ADO release are significantly 
reduced (Oliveira et al., 2015a). So, it is plausible that deficits in extracellular 
metabolism of ATP may operate in myasthenic animals. Figure 13 illustrates the time 
course of the extracellular catabolism of ATP and the formation of its metabolites on 
phrenic nerve-hemidiaphragm preparations of Naïve and EAMG rats. The ATP 
metabolites detected in the bath were ADP (Fig. 13B), AMP (Fig.13C), adenosine 
(ADO) (Fig.13D), inosine (INO) (Fig.13F) and hypoxanthine (HX) (data not shown), 
whose concentrations increased with time. The kinetics of the extracellular catabolism 
of ATP (30 µM) in EAMG rats was roughly similar to that of Naïve animals (Fig. 13A). 
ATP (30 µM) was metabolized with a half-degradation time of 8±2 min (n=8) in Naïve 
rats (Magalhães-Cardoso et al., 2003) and of 5±1 min (n=4) in EAMG animals (this 
study). Coincidence or not, we observed an increased accumulation of ADP in the bath 
effluent during the first 15 min after addition of the substrate in EAMG rats compared to 
Naïve animals (Fig. 13B).  
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Fig. 13- Time course of extracellular ATP  catabolism in phrenic nerve hemidiaphragm preparations from Naïve and EAMG 
animals.  ATP (30µM) was added at zero time to the preparation and samples were collected from the bath at the times indicated on 
the abscissa and retained for HPLC analysis. (A), (B), (C), (D), (E) and (F) show the kinetics of the extracellular ATP, ADP, AMP, 
ADO, IMP and INO, respectively. Shown is pooled data from a number of experiments (shown in parentheses). The vertical bars 
represent SEM and are shown when they exceed the symbols in size. 
 
No changes were observed in the rate of AMP (Fig. 13C), IMP (Fig. 13E) and ADO 
(Fig. 13D) formation in the two groups of animals. 
Among the plasma membrane bound NTPDases (NTPDases 1, 2, 3 and 8), NTPDase1 
(also named CD39, ATPDase, ecto- apyrase, ecto-ADPase) hydrolyzes ATP and ADP 
equally well, NTPDase2 is a preferential triphosphonucleosidase leading to transient 
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ADP accumulation, whereas NTPDase3 (CD39L3, HB6) and NTPDase8  are functional 
intermediates between NTPDases 1 and 2 (see Zimmermann, 2001). Thus, increased 
ADP accumulation from the extracellular ATP catabolism implicates a significant 
NTPDase 2 activity in EAMG animals. Confirmation of the NTPDase enzyme subtype 
most expressed in myasthenic rats needs further investigations.  
 
Overall, data presented so far indicate that deficits in the extracellular ATP metabolism 
by ectonucleotidases (NTPDases and ecto-5’-nucleotidase) are not responsible for the 
accumulation of the nucleotide in the incubation fluid during neuronal activity observed 
in EAMG animals. ATP can be released to the extracellular compartment by non-lytic 
mechanisms including: (1) exocytosis of ATP-containing vesicles; (2) through 
nucleotide-permeable channels (connexin and pannexin hemichannels, maxi-anion 
channels, volume regulated anion channels or P2X7 receptor channels); (3) via 
transport vesicles that deliver proteins to the cell membrane; (4) via lysosomes (Dahl 
and Muller, 2014; Penuela et al., 2013). One of these mechanisms can potentially be 
operating to increase evoked ATP release at motor endplates of EAMG animals. So, 
understanding which mechanisms underlies the increased release of evoked ATP in 
myasthenic conditions needs further investigation. 
 
Considering that ATP is able to modulate neuromuscular transmission through the 
activation of P2R (Salgado et al., 2000; Voss, 2009) or P1R through its conversion into 
ADO (Cunha et al., 1996a), it will be interesting to understand the dynamics of ATP 
neuromodulation of neuromuscular transmission.   
 
5.2. Neuromodulatory role of ATP on neuromuscular transmission 
in healthy and EAMG animals 
Exogenously applied ATP caused a biphasic effect on [3H]ACh release induced by 
phrenic nerve stimulation with 750 pulses applied with a 5Hz frequency (Fig.14A). Pre-
treatment of phrenic nerve hemidiaphragm preparations during 15 min with ATP (0.3-
30 µM) significantly increased evoked [3H]ACh release, in which the maximal 
facilitatory effect (56±7%, n=5) was observed when ATP was applied at 1 µM 
concentration. However, the increase of ATP concentration to 100 µM revealed an 
inhibitory effect on evoked [3H]ACh release (39±6%, n=7).  
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At the rat motor nerve terminals ATP is converted into ADO which activates P1R 
(Cunha et al., 1996a). In order to assess the ATP effect on neuromuscular 
transmission without the interference of the ATP-ADO-P1R pathway, the dose-
response curve of ATP was repeated in the presence adenosine deaminase (ADA, 0,5 
U/mL), the enzyme that inactivates the ADO into its inactive metabolite (Correia-de-Sá 
et al., 1996).  
Inactivation of ADO originated from the extracellular ATP catabolism with ADA (0,5 
U/mL) converted the facilitatory action of ATP (1 µM, 56±7%, n=5) into an inhibitory 
effect of (32±18%, n=4), suggesting that in absence of ADO a P2R action operated by 
ATP itself emerges (Fig. 14A).  
To further confirm this hypothesis we assessed the effect of a slowly hydrolysable 
analogue of ATP, βImidoATP, on evoked [3H]ACh release.  βImidoATP (30 and 100 
µM) concentration-dependently decreased [3H]ACh release from stimulated phrenic 
nerve endings of CTRL rats.  
 
 
 
 
 
 
 
Fig. 14- A- Concentration-response curve of ATP on electrically evoked (5 Hz, 750 pulses) [3H]ACh release from Naïve animals 
either in presence or absence of adenosine deaminase (ADA). ATP (0,3-100 µM) was applied 15 minutes before S2 and ADA (0,5 
U/mL) was applied 15 minutes before S1 and S2. Ordinates represent the percentage of effect of the nucleotide by comparing the 
S2/S1 ratios with the S2/S1 ration in absence or in the presence of ADA. Each point is the mean±SEM of 4 to 7 experiments. 
*P<0,05 (Student’s T-test). B- Effect of the stable βimidoATP  on electrically evoked (5 Hz, 750 pulses) [3H]ACh release from 
Naïve animals. βimidoATP  (30-100 µM) was applied 15 minutes before S2. Ordinates represent the percentage of effect of the 
βimidoATP  by comparing the S2/S1 ratios with the S2/S1 ration in absence on drugs. Each point is the mean±SEM of 3 
experiments. *P<0,05 (Student’s T-test). 
 
Moreover, if one shortens the incubation time with ATP (1 µM) from 15 to 3 min before 
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dephosphorylated into adenosine, the facilitatory effect (39±13%, n=7) no longer 
appeared and, instead, an inhibitory action (30±4%, n=7) emerges (Fig. 16).   
These results suggest that ATP modulates per se neuromuscular transmission by 
activating inhibitory P2R and, after being converted into adenosine, acts on P1R 
(probably A1R) to decrease evoked ACh release. It has been demonstrated that ATP 
exerts an inhibitory effect on both evoked (Sokolova et al., 2003) and spontaneous (De 
Lorenzo et al., 2006) ACh release from mouse motor nerve terminals via the activation 
of P2YR. Inhibitory couling to adenylate cyclase via Gi/o proteins are most probably 
involved in ATP-mediated inhibition of ACh release at the neuromuscular junction.  
ATP-sensitive P2Y12 and P2Y13 belong to the group of P2YR that preferentially couple 
to inhibitory Gi/o proteins (Burnstock, 2007). De Lorenzo and collaborators (2006) 
demonstrated that the pertussis toxin and N-etylmaleimide abolished the effect of β-
imido ATP suggesting that the P2YR involved in the presynaptic inhibition could be 
coupled to Gi/o protein. Despite, no pharmacological screening has been performed so 
far to characterize the subtype of P2YR at the mammalian neuromuscular junction, on 
may assume based on previous studies (De Lorenzo et al., 2006) that either P2Y12R or 
P2Y13R are the most probable receptors involved. 
Nevertheless, it should be noted that the predominant effect of exogenously applied 
ATP at 1 µM concentration is mediated by its metabolite ADO acting on facilitatory 
A2AR. The effect of ATP-sensitive P2YR on neuromuscular transmission is only 
observed under circumstances were no adenosine is available and/or A2AR activation is 
inoperant. These include (1) the lack of ADO formation (Fig. 14A), (2) in the presence 
of a slowly hydrolysable ATP analogues (Fig.14B), and (3) when the exposure time is 
not enough to allow the conversion of ATP into ADO (Fig.16). Prevalence of the 
facilitatory action of A2AR over P2R-mediated inhibition of evoked transmitter release 
from motor nerve endings implicates that the ATP inhibitory response must be shut-
down upon activation of A2AR by adenosine formed from the extracellular catabolism of 
the nucleotide. Previous results from our group demonstrated that adenosine A2AR on 
phrenic motor nerve terminals is positively coupled to Gs protein leading to activation of 
the AC/AMPC/PKA pathway (Correia-de-Sá and Ribeiro, 1994). On the other hand 
P2Y12R and P2Y13R are negatively coupled to Gi/o protein (Burnstock, 2007). Thus, it 
is likely that adenylyl cyclase is key enzyme operating the crosstalk between inhibitory 
P2YR and excitatory A2AR pathways leading to the prevalent facilitatory action of ATP 
on ACh release. Whether this crosstalk is perturbed in conditions where activation of 
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A2A receptors are impaired (e.g. myasthenia gravis) (Oliveira et al., 2015a), deserves to 
be investigated.  
To this end, we tested the effect of ATP (1 µM, applied during 15 min) either in 
presence or absence of ADA (0.5 U/mL) on evoked [3H]ACh release from phrenic 
nerve terminals of EAMG rats. Pre-treatment with ADA (0,5 U/mL) converted the 
facilitatory action of ATP (1 µM) (18±8%, n=5) into an inhibitory effect of (26±10%, n=4) 
in CFA animals. In EAMG rats, ATP (1 µM) applied 15 min prior stimulus delivery to the 
phrenic nerve facilitated [3H]ACh release by (43±12%, n=5) in the absence of ADA (0,5 
U/mL), but it failed to affect transmitter release when ADO was inactivated by ADA (0,5 
U/mL, 5±17%, n=4). We have previously reported that A2AR tonic activity is impaired in 
EAMG animals and it could be recovered by AMP application (Oliveira et al., 2015a). 
So, it was not surprising that ATP application rescued the facilitatory effect of A2AR 
activation.  
Interestingly, using a shorter incubation time (3 min) with ATP (1 µM), which decreases 
the conversion of ATP into ADP and AMP, and subsequently to ADO via de 
ectonucleotidase cascade in EAMG rats, reestablished the inhibitory effect (41±3%, 
n=2) obtained in both Naïve (30±4%, n=7) and CFA (26±10%, n=4) animals, under the 
same experimental conditions.  
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Fig. 15- Concentration-response curve of ATP on electrically evoked (5 Hz, 750 pulses) [3H]ACh release from Naïve, CFA and 
EAMG  animals either in presence or absence of adenosine deaminase (ADA). ATP (1 µM) was applied 15 minutes before S2 and 
ADA (0,5 U/mL) was applied 15 minutes before S1 and S2. Ordinates represent the percentage of effect of the nucleotide by 
comparing the S2/S1 ratios with the S2/S1 ration in absence or in the presence of ADA. Each point is the mean±SEM of 4 
experiments. *P<0,05 (Student’s T-test). 
 
Recently, it was reported that long exposition to ADP nucleotide triggers 
desensitization of P2Y12R (Hardy et al., 2005; Yu et al., 2014). In fact, we observed that 
during the first 15 minutes of ATP metabolism in EAMG animals there was a 
preferential ADP accumulation compared to Naïve rats (Fig.13B). Whether transient 
ADP accumulation, but not instantaneous ATP availability, in the extracellular milieu is 
sufficient to cause desensitization of P2YR in myasthenic neuromuscular junctions 
requires further investigations. 
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Fig. 16- Concentration-response curve of ATP on electrically evoked (5 Hz, 750 pulses) [3H]ACh release from Naïve, CFA and 
EAMG  animals. ATP (1 µM) was applied 3 minutes before S2. Ordinates represent the percentage of effect of the nucleotide by 
comparing the S2/S1 ratios with the S2/S1 ration in absence or in the presence of ATP. Each point is the mean±SEM of 7, 4 and 2 
experiments. *P<0,05 (Student’s T-test). 
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6. Conclusions and future work  
The major goal of this work was to provide the basis for better understanding the 
biochemical and molecular pathways concerning role of ATP on neuromuscular 
transmission in myasthenic animals. 
At the rat neuromuscular junction, adenosine inhibitory A1/excitatory A2A receptor 
activation balance is dependent on the stimulation pattern (Correia-de-Sá et al., 1996), 
which also tightly regulates the amount of extracellular adenosine build-up from the 
catabolism of released ATP (Cunha et al., 1996a; Magalhães-Cardoso et al., 2003). 
Previous reports from our group suggest that adenosine facilitation of ACh release 
operated by A2AR activation is impaired in individuals with myasthenia, a situation that 
can be rescued by incubation with ADO precursors, AMP (Noronha-Matos et al., 2011; 
Oliveira et al., 2015a) and ATP (this study). Released ATP modulates neuromuscular 
transmission either by directly activating P2 purinoceptors (P2R) (Salgado et al., 2000) 
or indirectly through the activation of P1 receptors after being metabolized into 
adenosine (ADO), via ecto-nucleotidases (Cunha et al., 1996a; Magalhães-Cardoso et 
al., 2003). This study show that lower endogenous adenosine amounts at myasthenic 
neuromusuclar junctions are not owe to significant changes in the kinetics of the 
extracellular metabolism of adenine nucleotides, nor to decreases in the release of 
ATP from stimulated preparations. The ultimate cause for deficits in adenosine to reach 
enough levels required to activate facilitatory A2A receptors may be excessive 
inactivation of the nucleoside by deamination and/or cellular uptake (Correia-de-Sá and 
Ribeiro, 1996).  
The signaling via extracellular nucleotides has been recognized for over a decade 
as one of the most ubiquitous intercellular signaling mechanisms (Lüthje, 1989; 
Burnstock et al., 2004). The inhibitory effects of ATP per se on ACh release may be 
mediated by P2Y receptors. From all P2YR subtypes, the most probably involved in the 
inhibitory action of ATP on neuromuscular transmission are the P2Y12R and P2Y13R, as 
these receptors couple negatively to adenylate cyclase via G(i/o) proteins (De Lorenzo 
et al., 2006) in contrast to all other subtypes that either activate PLC or AC via Gq/11 
and Gs proteins leading to increases of intracellular Ca2+ and transmitter release 
facilitation.  
Predominance of A2AR facilitation of transmitter release over P2YR-mediated 
inhibition in the presence of ATP may imply a negative crosstalk between these two 
purinoceptors, which deserves investigation in the near future. Whether this involves 
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homo- or hetero-desensitization of the P2YR requires further studies. Whatever the 
mechanism involved in this crosstalk, it might implicate the interplay at the adenylate 
cyclase activation level. 
Another issue that might be interesting investigating in the near future is the 
relationship between morphological changes of myasthenic endplates and their 
implications on the distribution of ATP release sites, nucleotidases and purinoceptors 
(purinome) at the perturbed synaptic microenvironment.  
Therefore, a detailed pharmacological characterization of inhibitory P2 receptors in 
myasthenic motor endplates becomes crucial to fully understand the pathophysiological 
consequences of the disease and to open the way for the development of new 
therapeutic strategies. This hypothesis certainly deserves further studies in the near 
future. 
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